Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 8/20 | 0.55 |
| ▸ | PPARA | Q07869 | 8/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | OSBP | P22059 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673043 | 1.00 | MAOA (0.66) | MAOAMAOBPTPN1PPARGPPARA | |
| SCHEMBL4254500 | 0.90 | PPARG (0.72) | MAOAMAOBPTPN1PPARGPPARA | |
| SCHEMBL4254498 | 0.90 | PPARG (0.72) | MAOAMAOBPTPN1PPARGPPARA | |
| SCHEMBL3670315 | 0.87 | PTPN1 (0.52) | MAOAMAOBPTPN1PPARGPPARA | |
| SCHEMBL3670316 | 0.87 | PTPN1 (0.52) | MAOAMAOBPTPN1PPARGPPARA | |
| SCHEMBL3671080 | 0.86 | PTPN1 (0.58) | MAOAMAOBPTPN1CYP19A1ALOX5 | |
| SCHEMBL3671081 | 0.86 | PTPN1 (0.58) | MAOAMAOBPTPN1CYP19A1ALOX5 | |
| SCHEMBL3673953 | 0.83 | PTPN1 (0.53) | MAOAMAOBPTPN1CYP19A1ALOX5 | |
| SCHEMBL3673951 | 0.83 | PTPN1 (0.53) | MAOAMAOBPTPN1CYP19A1ALOX5 | |
| SCHEMBL3669574 | 0.82 | PTPN1 (0.46) | MAOAMAOBPTPN1CYP19A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4425628-B2 | — | — | 2010-03-03 | — | — | JP | claimed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | claimed |
| JP-2005505519-A | — | — | 2005-02-24 | — | — | JP | claimed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAOA 575/4885MAOB 591/4885PTPN1 4044/4885 |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAOA 575/4885MAOB 591/4885PTPN1 4044/4885 |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAOA 575/4885MAOB 591/4885PTPN1 4044/4885 |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAOA 575/4885MAOB 591/4885PTPN1 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.